GNLX
$2.74
+$0.11 (4.18%)+4.18%
After HoursLoading chart...
IndexN/A
Market Cap0.12B
Enterprise Value0.16B
Income$-0.01B
Sales$0.00B
EmployeesN/A
P/E-3.22
P/S20261.21
P/B14.04
P/C-6.15
EV/EBITDA-5.02
EV/SalesN/A
EPS (ttm)-0.85
EarningsN/A
Gross Margin-7075.00%
Oper. Margin-415175.00%
Profit Margin-401812.50%
Volume0.46M
Shs Outstand0.04B
Change4.18%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $8.00K | $170.00K | $11.07M | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $903.00K | $1.02M | $968.00K | $895.00K | $658.00K | $0.00 |
| Gross Profit | $-895.00K | $-848.00K | $10.10M | $-895.00K | $-658.00K | $0.00 |
| Gross Margin | -11187.50% | -498.82% | 91.25% | N/A | N/A | N/A |
| Operating Expenses | $30.80M | $23.32M | $13.11M | $13.72M | $11.76M | $10.87M |
| Operating Income | $-31.70M | $-24.16M | $-3.01M | $-14.61M | $-12.42M | $-10.87M |
| Operating Margin | -396200.00% | -14214.71% | -27.22% | N/A | N/A | N/A |
| Net Income | $-29.87M | $-28.30M | $-5.21M | $-17.80M | $-14.86M | $-11.63M |
| Net Margin | -373362.50% | -16645.29% | -47.05% | N/A | N/A | N/A |
| EPS (Basic) | $-0.95 | $-1.16 | $-0.21 | $-0.69 | $-0.58 | $-0.49 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $34.72M | $27.89M | $5.53M | $8.13M | $14.01M | $3.28M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $8.44M | $8.42M | $41.31M | $41.24M | $36.66M | $28.09M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $26.27M | $19.47M | $-35.78M | $-33.11M | $-22.66M | $-24.81M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $26.27M | $19.47M | $-35.78M | $-33.11M | $-22.66M | $-24.81M |
| Total Liabilities & Stockholders Equity | $34.72M | $27.89M | $5.53M | $8.13M | $14.01M | $3.28M |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Net Income | $-29.87M | $-28.30M | $-5.21M | $-17.80M | $-14.86M | $-11.63M |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $-21.23M | $-20.27M | $-3.57M | $-6.58M | $-7.21M | $-7.22M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan PartnersGlobeNewswire Inc. Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical OfficerGlobeNewswire Inc. Genelux Corporation to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewswire Inc. Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2024GlobeNewswire Inc. Unveiling 4 Analyst Insights On GeneluxBenzinga Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying WarrantsGlobeNewswire Inc. Genelux Corporation Announces Proposed Public Offering of Common Stock and WarrantsGlobeNewswire Inc. Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business UpdatesGlobeNewswire Inc.
Show 12 more stories
Down -48.37% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a TurnaroundZacks Investment Research Down -45.44% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a TurnaroundZacks Investment Research After Plunging -26.21% in 4 Weeks, Here's Why the Trend Might Reverse for Genelux Corporation (GNLX)Zacks Investment Research All You Need to Know About Genelux Corporation (GNLX) Rating Upgrade to BuyZacks Investment Research Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateGlobeNewswire Inc. Why Quanex Building Products Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day SessionBenzinga THOR Industries Reports Upbeat Earnings, Joins Dave & Buster's Entertainment, Campbell Soup And Other Big Stocks Moving Higher On WednesdayBenzinga Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionBenzinga Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian CancerGlobeNewswire Inc. Why ReNew Energy Global Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Monday's Mid-Day SessionBenzinga Chegg, Perdoceo Education And Other Big Stocks Moving Lower On MondayBenzinga Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business UpdatesGlobeNewswire Inc.
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.
Discover more
You may be interested in